相关实验视频

Updated: Jan 14, 2026

Scanning Skeletal Remains for Bone Mineral Density in Forensic Contexts

Scanning Skeletal Remains for Bone Mineral Density in Forensic Contexts

Published on: January 29, 2018

在对少量基于脂质的营养补充剂试验的元分析中,使用身高年龄而不是身高年龄z-score来量化儿童生长效应

Kelly M Watson^1,2, Alison S B Dasiewicz¹, Diego G Bassani^1,3,4

¹Centre for Global Child Health, The Hospital for Sick Children, 686 Bay St, Toronto, ON, M5G 0A4, Canada.

Scientific reports

|October 22, 2025

概括

高度年龄是一种新的指标,与长度对年龄z-score (LAZ) 相比,它可以更清楚地了解干预对儿童成长的影响. 这项研究表明,少量基于脂质的营养补充剂 (SQ-LNS) 实现了11%的最佳生长潜力.

科学领域:

儿童营养学儿童营养学
增长监测增长监测增长监测
公共卫生干预公共卫生干预

背景情况:

儿童的线性生长不稳定是一个重要的全球健康问题,特别是在低收入和中等收入国家 (LMICs).
传统的指标,如长度对年龄z-scores (LAZ) 被广泛使用,但可能缺乏对干预效应的直观解释性.
高龄提供了线性增长的另一种表达方式,有可能提高对干预影响的理解.

研究的目的:

在评估线性增长结果时,将高龄的效用和最大效益 (PMB) 与LAZ的比例进行比较.
通过使用这些不同的指标,评估少量基于脂质的营养补充剂 (SQ-LNS) 的有效性.

主要方法:

对LMIC中涉及SQ-LNS干预的随机对照试验 (RCT) 进行了元分析.
计算了身高年龄和PMB,并与传统的LAZ分数进行了比较.
在15项试验中进行了统计相关性和异质性分析.

主要成果:

在LAZ和身高年龄的平均差异 (MD) 显示出强烈的相关性 (rho = 0.74),表明指标之间的一致性.
聚合的PMB表明,SQ-LNS干预实现了最佳增长潜力的11%.
在试验之间观察到显著的异质性 (I2 = 90%),突出显示了干预效应的变化.

结论:

与LAZ相比,高龄提供了线性生长结果的另一种,可能更易于解释的表达方式.
PMB指标量化了相对于生物潜力的干预有效性,提高了可解释性.
需要进一步的研究来确定高龄和PMB的有效性和实用性,以便进行干预评估和比较.

关键词:

孩子的成长孩子的成长高度年龄的高度年龄.根据年龄的身高进行z分数.长度为年龄的z-分数低收入和中等收入国家.随机对照试验是随机对照试验.小量基于脂质的营养补充剂

更多相关视频

Assessment of Child Anthropometry in a Large Epidemiologic Study

Assessment of Child Anthropometry in a Large Epidemiologic Study

Published on: February 2, 2017

Real Time and Repeated Measurement of Skeletal Muscle Growth in Individual Live Zebrafish Subjected to Altered Electrical Activity

Real Time and Repeated Measurement of Skeletal Muscle Growth in Individual Live Zebrafish Subjected to Altered Electrical Activity

Published on: June 16, 2022

相关概念视频

Drug Dosing: Infants and Children

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...

Nature and Nurture

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...

Pharmacokinetics in Pediatric Patients: Drug Distribution

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...

Pharmacokinetics in Pediatric Patients: Drug Metabolism

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...